Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 5 distinct art units, indicating a breadth of specialized subject matter within the life sciences sector. The prosecution work is handled by 7 distinct examiners, which suggests a highly diversified review process where no single examiner holds a majority of the pending workload.
TIMOTHY R ROZOF is identified as the busiest examiner for this portfolio, though he is responsible for only 1 pending office action. Because the workload is spread across many individuals, the applicant faces a wide variety of individual examination styles and preferences. This distribution across 5 distinct art units requires a prosecution strategy that accounts for different internal policies and technical standards within the USPTO Biotechnology & Pharmaceuticals divisions. The fact that every current case is being evaluated by a unique set of eyes maximizes the diversity of feedback received by the institute. This decentralized approach ensures that the 7 pending office actions are not subject to the potential bottleneck of a single examiner's schedule.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §102 only | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| COOK, LISA V | 1 | 67.6% | +9.9% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 5d overdue |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 2d overdue |
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | — |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
| 17920356 | Exosome Analysis And Brain Tumors | COOK, LISA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 5d overdue |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 2d overdue |
| 18862234 | Combination Of Curaxins And Immune Checkpoint Inhibitors For Treating Cancer | ROZOF, TIMOTHY R | — |
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | — |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1642 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862234 | Combination Of Curaxins And Immune Checkpoint Inhibitors For Treating Cancer | ROZOF, TIMOTHY R | — | §102 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18715013 | COMBINATION THERAPY FOR CANCER TREATMENT | WELLS, LAUREN QUINLAN | — | §103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18287508 | Malignant Mesothelioma Susceptibility As A Result Of Germline Leucine-Rich Repeat Kinase 2 (LRRK2) Alterations | GOLDBERG, JEANINE ANNE | 1682 | §103§112 | Final Rejection | — | Pending | Oct 19, 2023 |
| 17920356 | Exosome Analysis And Brain Tumors | COOK, LISA V | 1642 | §101§103§112 | Non-Final OA | — | Pending | Oct 20, 2022 |
| 17613267 | PI3K/LYN-ACLY Signaling Inhibition | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Non-Final OA | 5d overdue | Pending | Nov 22, 2021 |
| 17527536 | THEOPHYLLINE DERIVATIVES FOR REPRESSING CANCER CELL GROWTH | PECKHAM, RICHARD GRANT | 1627 | §103§112 | Final Rejection | 2d overdue | Pending | Nov 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial